Profile avatar
araymakers.bsky.social
Health economist & research fellow with the Program on Regulation, Therapeutics, & Law (PORTAL) at Harvard Medical School. Interests: drug pricing/policy, health technology assessment, climate change and healthcare. www.linkedin.com/in/araymakers
85 posts 1,916 followers 754 following
Prolific Poster
Conversation Starter
Posts 40 Comments 10

Don't miss an opportunity to work with our renowned faculty! Applications for our 2025 CEA Registry Summer Fellowship close March 17th. Learn more / apply today: cevr.tuftsmedicalcenter.org/news/2025-ce... #internships #fellowship #healthecon @peterneumann11.bsky.social @pattysynnott.bsky.social

submitted 15 hours ago • 0 comments

In B.C., the abortion pill Mifegymiso is available at all hospitals, health centres and clinics. The pill is also available for free at all pharmacies. Pharmacists are able to prescribe Mifegymiso to their patients at no cost. In the Yukon access is slim, at best. www.cbc.ca/news/canada/...

submitted 16 hours ago • 0 comments

"People who work on Medicare drug price negotiations, help Medicare beneficiaries over the phone, analyze lab regulations, and work on data science were all part of the initial terminations...", despite the admin's claims it wasn't firing people working on Medicare. www.statnews.com/2025/03/01/f...

submitted 2 days ago • 0 comments

Well, an earthquake wasn't on today's bingo card but here we are.

submitted 10 days ago • 0 comments

Really important work to understand the far-reaching impact of wildfires. #ClimateCrisis

submitted 11 days ago • 0 comments

Universities too. #edusky

submitted 11 days ago • 0 comments

"We shall, as an editorial team, stay abreast of changes in this very dynamic environment and adapt as needed to ensure that we will continue to meet the needs of science and health communication, guided always by our responsibility to the health of patients and the public worldwide."

submitted 11 days ago • 0 comments

A note on this Fierce Pharma piece on new approaches to cost-effectiveness analysis. The article refers to the new approach as a 'societal perspective'. That's not quite accurate. They'd be better described as a 'manufacturer' or 'industry' perspective. www.fiercepharma.com/pharma/leeri...

submitted 12 days ago • 1 comment

Periodic reminder that I have a great group of MPH students actively looking for summer internships/practicums in health policy — please share if you have any open or upcoming applications!

submitted 12 days ago • 2 comments

Cost-effectiveness analysis is useful, QALYs are too, Please don’t ban their use, Let’s work together toward sustainable healthcare for me & you. #HealthPolicyValentines

submitted 383 days ago • 0 comments

🚨 Job opportunity! 🚨 Minnesota is seeking out an Executive Director for its Prescription Drug Affordability Board. #PDAB #Healtheconomics #HSPR Link: careers.mn.gov/psp/mnjob/MN...

submitted 17 days ago • 0 comments

Great new paper in @nejm.org by @yashaswini.bsky.social et al. about PE in healthcare internationally. My two take-aways: ► PE will invest wherever it can find opportunities, so public provision may be a buffer. ► More transparency around ownership structures needed. www.nejm.org/doi/full/10....

submitted 18 days ago • 0 comments

"We found that taxpayers and private charities like Sophia’s Cure subsidized much of the science that yielded Zolgensma, providing research grants and opening the door to federal tax credits and other benefits that sped its path to approval." via @propublica.org www.propublica.org/article/zolg...

submitted 19 days ago • 0 comments

'Judge halts some NIH cuts after 22 states sue' @endpts.com endpts.com/judge-halts-...

submitted 21 days ago • 0 comments

Come be my new boss! @sfu-fhs.bsky.social is searching for a new Dean. Located in metro Vancouver, Canada, we're a highly productive and collegial community with a commitment to improve the health of individuals and populations and to reduce health inequities with a commitment to social justice.

submitted 21 days ago • 2 comments

Thanks for the kind words Peter! And also thank you for the Tufts CEA Registry - it was an invaluable resource in writing this paper!

submitted 24 days ago • 0 comments

👀

submitted 25 days ago • 0 comments

Criticism of the QALY includes the idea that it'll be used to limit drug access to patient subgroups, but @araymakers.bsky.social shows in J Cancer Policy that no evidence of QALYs in cancer drugs being used to do that -- from @portalresearch.org: www.sciencedirect.com/science/arti...

submitted 27 days ago • 0 comments

UPDATED: How does U.S. life expectancy compare to other countries? Hint: not great. www.healthsystemtracker.org/chart-collec...

submitted 28 days ago • 3 comments

🚨 Just out today (online)! 🚨 Our results show that a common argument against #QALYs (based on the use of subgroup analyses) is not justified with empirical data. With co-authors: @leah-rand.bsky.social , @wbfeldman.bsky.social, & @akesselheim.bsky.social from @portalresearch.org.

submitted 31 days ago • 1 comment

Thank you for your invaluable contributions @akesselheim.bsky.social and team @portalresearch.org It is a great pleasure to work with you all @repo4eu.bsky.social @sabine-e-grimm.bsky.social @araymakers.bsky.social

submitted 33 days ago • 0 comments

Had an interesting discussion about cost-minimization analysis in the context of HTA yesterday which reminded me of writing this article a few years back! (with co-authors from @lshtm.bsky.social and @uniofgalway.bsky.social). www.sciencedirect.com/science/arti... #healtheconomics

submitted 33 days ago • 1 comment

Breaking: The Sackler family and the bankrupt drugmaker they own, Purdue Pharma, have struck a new $7.4 billion agreement to settle mass opioid litigation

submitted 39 days ago • 3 comments

On the left: What Merck is doing around Keytruda On the right: The definition of product hopping and patent evergreening

submitted 40 days ago • 1 comment

Really positive teaching reviews were very welcome today. 🎉

submitted 41 days ago • 1 comment

Franke made a mid ride mod (i.e., clawed a hole) in her new trailer. Much better now.

submitted 42 days ago • 2 comments

Super interesting new paper by Edward Xie (@edwardxie.bsky.social) and colleagues just out in the BMJ Global Health.🌎 "Net Zero is not enough: ratcheting ambition for sustainable health systems through Reduce and Support" gh.bmj.com/content/8/Su...

submitted 47 days ago • 1 comment

This is an outstanding opportunity to work with outstanding faculty incl @jacobwswallace.bsky.social in a dynamic department here @yalesph.bsky.social 👇 🧪🛟📈📉 #econsky #academicsky #healthpolicysky

submitted 49 days ago • 1 comment

Really cool paper about immortal time bias just out in Epidemiology by @miguelhernan.org et al. Definitely worth a read! pubmed.ncbi.nlm.nih.gov/39494894/

submitted 52 days ago • 1 comment

#ARM25 abstract submissions deadline is fast approaching! Submit by 1/8 at 5pm ET to attend the 2025 Annual Research Meeting (ARM) in Minneapolis, MN: academyhealth.org/page/2025-ar... Learn more about why students should attend ARM here: academyhealth.org/blog/2024-12...

submitted 56 days ago • 0 comments

Pre-ordered! Excited to read Jerry's new book! @portalresearch.org

submitted 54 days ago • 0 comments

We're recruiting for 2 postdoctoral researchers to join the Mitigating Air Pollution Impact Project, underpinned by a public health approach to air pollution mitigation & adaptation, enabling consideration of equity, from a policy perspective. @epaireland.bsky.social @irishdocsenv.bsky.social

submitted 55 days ago • 1 comment

The Call for Abstracts is out for the Highland Health Economics Symposium (June 9-12, 2025 in Oban, Scotland). Submit abstracts by March 1. Decisions by March 31. The invite link is here: t.co/4NRpoUtguF Organized by David Bradford, Fiona Scott Morten, Steve Parente, and Bob Town.

submitted 56 days ago • 1 comment

Hey! I made this starter pack for folks interested in #SustainableMedicine #SustainableHealthcare. Join in, and say hello! Not exactly sure how it works. Let me know if you want in! :) go.bsky.app/BZyi1Px

submitted 76 days ago • 0 comments

Is there a way to find out if you've been added to someone's 'starter pack' or list? I've woken up to 100 new followers and assuming that's why. I doubt it's my dog photos! 😂

submitted 62 days ago • 3 comments

Green Christmas.

submitted 65 days ago • 0 comments

Great work on trends in 🇨🇦 drug spending by Mina Tadrous et al! 'Without measures to address this ongoing increase in pharmaceutical spending, there may be a need to reallocate funds from other public sectors or shift costs to private industry & patients.' canjhealthtechnol.ca/index.php/cj...

submitted 70 days ago • 0 comments

Curious about cost-effectiveness thresholds? There's lots of misconceptions and misinterpretations about what they are (& what they aren't). Check out this excellent post by Dr Jacoline Bouvy - 'Programme director for medicines evaluation' at NICE. #healtheconomics www.nice.org.uk/news/blogs/s...

submitted 75 days ago • 0 comments

🚨New @portalresearch.org paper🚨 in JAMA Health Forum. HIGHLIGHTS: 🔵 Biosimilars made up <2% of adalimumab use in 2023. 🔵 Net prices dropped by >40%...but the Humira list price increased. Meaning: Abbvie payed confidential rebates to maintain Humira dominance. 💊🩺📊 📜 jamanetwork.com/journals/jam...

submitted 80 days ago • 1 comment

This looks like an incredible opportunity for health economists (including ECRs!) to do some research in Australia! #healtheconomics #hspr

submitted 82 days ago • 0 comments